Vera Therapeutics VERA 深 沪
已收盘 11-13 16:00:00 美东时间
28.10
-0.940
-3.24%
华盛通- 最 高28.96
- 今 开28.64
- 成交量 101.36万股
- 最 低 27.85
- 昨 收 29.04
- 总市值 203.16万
- 52周最高 56.05
- 市盈率 静 --
- 换手率 1401.90%
- 52周最低 26.375
- 委 比 -59.60%
- 总股本 7.23万
- 历史最高 56.05
- 量 比 0.64
- 振 幅 3.82%
- 历史最低 5.20
- 每 手 1
- 风险率 6.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 巴克莱维百济神州"超配"评级！目标价从415美元上调至446美元
今日重点评级关注：瑞银：维持Liberty Media"中性"评级，目标价从110美元升至1116美元；杰富瑞：维持伊诺维奥制药"买入"评级，目标价从3美元升至8美元
11-09 14:00
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics granted inducement awards, including 14,900 non-qualified stock options and 7,450 RSUs, to three new employees under the 2024 Inducement Plan. The stock options and RSUs vest over four years, with options priced at $30.25 per share. Vera Therapeutics is a biotech company focused on autoimmune diseases, particularly kidney-related conditions, and markets TRUTAKNA®.
11-06 21:05
财报速睇 | Vera Therapeutics 2026财年Q3营收0.10亿美元；归母净利润亏损0.94亿美元，同比亏损扩大16.71%
华盛资讯11月6日讯，Vera Therapeutics公布2026财年Q3业绩，公司Q3营收0.10亿美元，归母净利润亏损0.94亿美元，同比亏损扩大16.71%。
11-06 08:20
财报速睇 | Vera Therapeutics 2026财年Q3营收0.10亿美元；归母净利润亏损0.94亿美元，同比亏损扩大16.7%
华盛资讯11月6日讯，Vera Therapeutics公布2026财年Q3业绩，公司Q3营收0.10亿美元，归母净利润亏损0.94亿美元，同比亏损扩大16.7%。
11-06 05:34
Vera Therapeutics Q3 EPS $(1.30) Beats $(1.62) Estimate, Sales $10.277M Beat $3.398M Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.30) per share which beat the analyst consensus estimate of $(1.62) by 19.75 percent. This is a 3.17 percent decrease over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $10.277 milli...
11-06 05:09
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Vera Therapeutics announced that its management team will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026, at 11:30 AM ET. The event will be available via webcast and replay for 90 days. Vera Therapeutics is a biotech company focused on autoimmune diseases, with its flagship product TRUTAKNA targeting kidney-related conditions. The company is evaluating TRUTAKNA's potenti...
11-02 13:00
Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks
Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy (IgAN) at risk for disease progression was presented as a featured late-breaking oral presentati...
10-22 22:06
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
Vera Therapeutics announced that TRUTAKNA, the first FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints in the ORIGIN 3 trial for adults with primary IgA nephropathy (IgAN). The drug demonstrated favorable safety, with adverse events comparable to placebo, and a plan to submit a supplemental BLA in Q4 2026 for full approval in 2027. An investor webcast is scheduled for October 22.
10-22 14:05
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34
Leerink Partners analyst Will Soghikian initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Market Perform rating and announces Price Target of $34.
10-12 20:22
